Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2005

View Archived Issues

Phase III ferumoxytol program recommended to continue by DMC

Cetilistat successfully completes U.S. study in obese subjects

ABT-894 begins phase I multidose trial for neuropathic pain

Triad Pharmaceuticals changes name to Arisaph Pharmaceuticals

European orphan drug designation for Bronchitol in cystic fibrosis

Phase I study for EVT-101

Phase III ACCLAIM trial of Celacade technology reaches target endpoint events

More sites for PROVIDENCE-1 study of rifalazil in intermittent claudication

Phase I study for NGX-424 for intractable pain

Promising antinociceptive effects of a novel P2X7 receptor antagonist from Abbott

CYC-116 begins IND-directed preclinical development

Fuji Pharma and JCR dissolve codevelopment agreement for JR-013

M-43068: A novel analgesic agent with reduced side effect profile

JDY-8112 protects dopaminergic neurons against inflammatory damage

AMG-0347: a novel, potent and selective TRPV1 antagonist

FDA approves new indication for Invanz

Novel histamine H3 receptor antagonists revealed by Lilly

Priority review granted for Japanese Baraclude submission

AP-23573 receives E.U. orphan drug designation for soft-tissue and bone sarcomas

Approvable letter for Thalomid sNDA for multiple myeloma

Procoralan receives European approval for chronic stable angina

New data support the use of sulodexide in the treatment of diabetic nephropathy

First data on the E1E2/MF59C.1 hepatitis C vaccine in humans

New data on the antiviral effects of Albuferon plus ribavirin in chronic hepatitis C

HepeX-B shows promise in the prevention of immune escape in HBV-infected patients

Interferon omega effective in phase II chronic hepatitis C study

Polyenylphosphatidylcholine improves peginterferon-ribavirin HCV treatment

Telbivudine superior to lamivudine in phase III hepatitis B trial

Novel agents for the treatment of neurological disorders disclosed in recent patents

Novel therapeutics for gastrointestinal disorders claimed in recent Altana patent

Novel agents for HIV infection imparted in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...